Nine ideas to improve the clinical management of HIV infected patients during the COVID-19 pandemic

Globally, in 2019, HIV infection was still responsible for 1.7 million new infections 2.2 and for 690,000 deaths in the same year. Tailored and new antiretroviral therapy (ART) regimens, individualised follow-up and new technologies to support data-sharing between health—care professional caring for people living with HIV (PLHIV) and to deliver ART to patients are desperately needed to reach the 90-90-90-90 ambitious goals. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, responsible for the Coronavirus-19 (COVID-19) pandemic that spread globally in 2020, posed a huge challenge for PLHIV and HIV physicians worldwide in terms of continuum of care.In this paper we encourage “up-to-date patient-centred HIV medicine” and we give nine ideas to improve HIV management in clinical practice during the COVID-19 pandemic

REAL-TIME ELASTOGRAPHY IN THE ASSESSMENT OF LIVER FIBROSIS: A REVIEW OF QUALITATIVE AND SEMI-QUANTITATIVE METHODS FOR ELASTOGRAM ANALYSIS

Despite its invasiveness, liver biopsy is still considered the gold standard for the assessment of hepatic fibrosis. Non-invasive ultrasound-based techniques are increasingly employed to assess parenchymal stiffness and the progression of chronic diffuse liver diseases. Real-time elastography is a rapidly evolving technique that can reveal the elastic properties of tissues. This review examines qualitative and semi-quantitative methods developed for analysis of real-time liver elastograms, to estimate parenchymal stiffness and, indirectly, the stage of fibrosis. Qualitative analysis is the most immediate approach for elastogram analysis, but this method increases intra- and inter-observervariability,whichisseenasamajorlimitationofreal-timeelastography.Semi-quantitativemethods include analysis of the histogram derived from color-coded maps, as well as calculation of the elastic ratio and fibrosis index. (E-mail: [email protected]) 2014 World Federation for Ultrasound in Medicine & Biology

Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: A multicenter regional simulation

Objectives: Chronic hepatitis C virus (HCV) is a leading cause of hospitalization and death in populations coinfected with human immunodeficiency virus (HIV). Sofosbuvir (SOF) is a pan-genotypic drug that should be combined with other agents as an oral treatment for HCV. We performed a 5-year horizon budget impact analysis of SOF-based regimens for the management of HIV/HCV-coinfected patients. Methods: A multicenter, prospective evaluation was conducted, involving four Italian Infectious Diseases Departments (Galliera, San Martino, Sanremo, and La Spezia). All 1,005 genotype-coinfected patients (30% cirrhotics) under observation were considered (patients in all disease-stages were considered: chronic hepatitis C, cirrhosis, transplant, hepatocellular carcinoma). Disease stage costs per patient were collected; the expected disease progression in the absence of treatment and sustained virological response (SVR) success rate for SOF-based regimens were calculated based on the literature and expert opinion. Drug prices were based on what the National Health Service paid for them. The comparison of \u201cno treatment\u201d disease progression costs versus the economic impact of SOF-based regimens was investigated. Results: Over the following 5 years, the disease progression scenario resulted in direct costs of approximately \u20ac54 million. Assuming an SVR success rate of 90%, average SOF-based regimens cost up to \u20ac50,000 per person, resulting in a final cost of more than \u20ac56 million, so this option is not economically viable. At the average price of \u20ac12,000, SOF-based regimens, expense was \u20ac17 million, saving 68%. At this price level, the economic resources invested in treating mild to moderate fibrosis stage patients would be equal to the amount of direct costs of disease management in this stage, resulting in a valid return of investment in the short-term. Conclusion: Given the high rates of SVR, in the Italian Healthcare System, SOF-based regimens, price is a determinant and a predictor of the overall cost for the Hepatitis C patient\u2019s management. At the average price per therapy of \u20ac12,000 over the next 5 years, SOF-based regimens are becoming highly sustainable

Is it still worthwhile to perform quarterly CD4+ T lymphocyte cell counts on HIV-1 infected stable patients?

Background: In the last twenty years routine T CD4+ lymphocyte (CD4) cell count has proved to be a key factor to determine the stage of HIV infection and start or discontinue of prophylaxis for opportunistic infections. However, several studies recently showed that in stable patients on cART a quarterly CD4 cell count monitoring results in limited (or null) clinical relevance. The research is intended to investigate whether performing quarterly CD4 cell counts in stable HIV-1 patients is still recommendable and to provide a forecast of the cost saving that could be achieved by reducing CD4 monitoring in such a category of patients. Methods: The study is based on data referring to all HIV-infected patients > 18 years of age being treated at two infectious diseases units located in the metropolitan area of Genoa, Italy. The probability of CD4 cell counts dropping below a threshold value set at 350 cells/mm3 is assessed using confidence intervals and Kaplan-Meier survival estimates, whereas multivariate Cox analysis and logistic regression are implemented in order to identify factors associated with CD4 cell count falls below 350 cells/mm3. Results: Statistical analysis reveals that among stable patients the probability of maintaining CD4 >350 cell/mm3 is more than 98%. Econometric models indicate that HCV co-infection and HIV-RNA values >50 copies/mL in previous examinations are associated with CD4 falls below 350 cells/mm3. Moreover, results suggest that the cost saving that could be obtained by reducing CD4 examinations ranges from 33% to 67%. Conclusions: Empirical findings show that patients defined as stable at enrollment are highly unlikely to experience a CD4 value <350 cell/mm3 in the space/arc of a year. The research supports a recommendation for annual CD4 monitoring in stable HIV-1 patients

Cost per care of the first year of direct antiviral agents in the liguria region: A multicenter analysis

Aims: Despite the remarkable efficacy shown in clinical practice, concerns have been raised about the costs associated with direct antiviral agent (DAA) therapy. This article presents the real-life costs for DAA treatment sustained by the Italian National Health Service in the Liguria Region (Northern Italy). Methods: A retrospective analysis of the cost per care sustained for DAA treatment, relating to the period from January 1 to December 31, 2015 in five centers in Liguria was performed. All patients undergoing DAA-based treatments for hepatitis C virus (HCV) infection were enrolled. On-treatment costs included: HCV treatment, laboratory test, outpatient services, attended visits, drugs used for the management of adverse events (erythropoietin, albumin or red blood cell packs) and inpatient service admissions. Results: In total, 327 patients were enrolled. No difference in terms of sustained virologic response (SVR) rate among different treatments was reported. The majority (85.0%) of patients did not report any side effects and only 15 (4.6%) required hospital admission. Forty-two patients (12.8%) required high-cost drugs for the management of adverse events. The overall cost sustained was \u20ac14,744,433. DAA\ub1ribavirin (RBV) accounted for the wide majority of this cost (98.9%; \u20ac14,585,123). Genotype (GT) 1, the most commonly treated GT, was associated with an average cost of \u20ac43,445 per patient. Detailed analysis of the costs for GT 1 showed the treatment based on ritonavir boosted paritaprevir/ombitasvir + dasabuvir\ub1RBV with an average cost of \u20ac24,978 (RBV+) and \u20ac25,448 (RBV 12) per patient was the most cost-effective. The average cost per SVR was \u20ac48,184. Once again, the ritonavir boosted paritaprevir/ ombitasvir + dasabuvir regimen was associated with the lowest cost/SVR (\u20ac25,448/SVR [GT 1b] and similar results for other GTs). Conclusion: Antiviral regimen is the major contributor to costs in the treatment of HCV infection. Appropriate regimen selection could result in a major cost saving, which can be reinvested to allow more patients to be treated

Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing

Time to change the single-centre approach to TB http://ow.ly/lCeM30hBcbB

Penerapan Metode Peer Teaching Untuk Meningkatkan Hasil Belajar Kognitif Siswa Pada Mata Pelajaran Pendidikan Agama Islam Materi Puasa Wajib dan Puasa Sunah : Penelitian Tindakan Kelas di Kelas VIII-G (Delapan) SMPN 31 Bandung

Masalah yang sangat menonjol yang di hadapi dalam pelajaran PAI yang bermula dari fenomena yang muncul di lapangan yaitu hasil belajar siswa yang masih rendah. Hal ini terlihat dari hasil belajar siswa dan hasil ulangan siswa masih banyak yang berada di bawah KKM 76 hampir 70%. Salah satu faktor yang mempengaruhi hasil belajar siswa adalah metode yang sesuai. Oleh karena itu, diperlukan metode yang baru dan interaktif, agar pemahaman siswa pada materi pelajaran menjadi optimal sehingga hasil belajar mereka pun dapat meningkat sesuai dengan yang diharapkan. Penelitian ini bertujuan untuk mengetahui (1) Hasil belajar kognitif siswa sebelum diterapkan metode Peer Teaching pada mata pelajaran PAI siswa kelas VIII-G; (2) Proses pembelajaran siswa kelas VIII-G dengan menggunakan metode Peer Teaching pada mata pelajaran PAI siswa kelas VIII-G; (3) Hasil belajar kognitif siswa kelas VIII-G pada mata pelajaran PAI setelah diterapkan metode Peer Teaching. Metode peer teaching dinilai dapat dimanfaatkan sebaik-baiknya dalam pelajaran Pendidikan Agama Islam. Kelebihan dari metode ini adalah (1) Meningkatkan motivasi belajar siswa; (2) Meningkatkan kualitas dan proses pembelajaran; (3) Meningkatkan hasil belajar. Penelitian ini merupakan Penelitian Tindakan Kelas yang dilakukan dalam 3 siklus. Setiap siklus terdiri dari 1 pertemuan dengan tahapan-tahapan (1) Perencanaan; (2) Tindakan; (3) Observasi; (4) Refleksi. Tahapan-tahapan ini dilakukan untuk meningkatkat hasil belajar kognitif siswa pada mata pelajaran PAI materi Puasa Wajib dan Puasa Sunah. Setelah melakukan penelitian, disimpulkan bahwa (1) hasil belajar kognitif siswa sebelum diterapkannya metode Peer Teaching masih banyak siswa yang mendapatkan nilai di bawah rata-rata KKM, (2) Proses pembelajaran dengan menggunakan metode Peer Teaching setiap siklusnya mengalami peningkatan yang sangat signifikan, dengan kegiatan intinya adalah siswa di bantu oleh temannya sendiri ketika belajar di kelas dan (3) Hasil belajar kognitif siswa setelah diterapkan metode Peer Teaching yaitu setiap siklusnya mengalami peningkatan, terlihat pada siklus I dengan rata-rata 72.37 termasuk kategori baik, ketuntasan belajar klasikal sebesar 36.84% dengan jumlah 14 siswa tuntas belajar, siklus II nilai rata-rata meningkat menjadi 80 termasuk kategori sangat baik, sehingga nilai rata-rata dari siklus I ke siklus II meningkat sebesar 7.63%, ketuntasan belajar klasikal sebesar 86.84% dengan jumlah 33 siswa tuntas belajar sehingga ketuntasan belajar klasikal dari siklus I dan II meningkat sebesar 50%, dan siklus III terjadi peningkatan nilai rata-rata yang signifikan menjadi 96.05 termasuk kategori sangat baik, sehingga nilai rata-rata dari siklus II ke siklus III meningkat sebesar 16.05% semua siswa masuk pada kategori tuntas sehingga persentasi kelulusan 100%. Dengan demikian, pembelajaran Pendidikan Agama Islam dengan menggunakan metode peer teaching dapat meningkatkan hasil belajar kognitif siswa

Edge reductions in cyclically k-connected cubic graphs

AbstractThis paper examines edge reductions in cyclically k-connected cubic graphs, focusing on when they preserve the cyclic k-connectedness. For a cyclically k-connected cubic graph G, we denote by Nk(G) the set of edges whose reduction gives a cubic graph which is not cyclically k-connected. With the exception of three graphs, Nk(G) consists of the edges in independent k-edge cuts. For this reason we examine the properties and interactions between independent k-edge cuts in cyclically k-connected cubic graphs. These results lead to an understanding of the structure of G[Nk]. For every k, we prove that G[Nk] is a forest with at least k trees if G is a cyclically k-connected cubic graph with girth at least k + 1 and Nk ≠ ⊘. Let fk(ν) be the smallest integer such that |Nk(G)| ≤ fk(ν) for all cyclically k-connected cubic graphs G on ν vertices. For all cyclically 3-connected cubic graphs G such that 6 ≤ ν(G) and N3 ≠ ⊘, we prove that G[N3] is a forest with at least three trees. We determine f3 and state a characterization of the extremal graphs. We define a very restricted subset N4b of N4 and prove that if N4g = N4 − N4b ≠ ⊘, then G[N4g] is a forest with at least four trees. We determine f4 and state a characterization of the extremal graphs. There exist cyclically 5-connected cubic graphs such that E(G) = N5(G), for every ν such that 10 ≤ ν and 16 ≠ ν. We characterize these graphs. Let gk(ν) be the smallest integer such that |Nk(G)| ≤ gk(ν) for all cyclically k-connected cubic graphs G with ν vertices and girth at least k + 1. For k ∈ {3, 4, 5}, we determine gk and state a characterization of the extremal graphs

Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

Background In persons living with HIV (PLWH), the burden of non-communicable chronic diseases increased over time, because of aging associated with chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART). Methods To explore the association of chronological age, age at first ART, and exposure to ART with non-communicable chronic diseases, we performed a cross-sectional analysis to evaluate the prevalence of comorbidities in patients enrolled in the SCOLTA Project, stratified by groups of chronological age (50-59 and 60-69 years) and by years of antiretroviral treatment (ART, <= 3 or > 3 years). Results In 1394 subjects (23.8% women), mean age at enrollment was 57.4 (SD 6.5) years, and at first ART 45.3 (SD 10.7). Men were older than women both at enrollment (57.6 vs 56.8, p = 0.06) and at first ART (45.8 vs 43.6, p = 0.0009). ART duration was longer in women (13.1 vs 11.7 years, p = 0.01). The age- and sex-adjusted rate ratios (aRRs, and 95% confidence interval, CI) showed that longer ART exposure was associated with dyslipidemia (aRR 1.35, 95% CI 1.20-1.52), hypertension (aRR 1.52, 95% CI 1.22-1.89), liver disease (aRR 1.78, 95% CI 1.32-2.41), osteopenia/osteoporosis (aRR 2.88, 95% CI 1.65-5.03) and multimorbidity (aRR 1.36, 95% CI 1.21-1.54). These findings were confirmed in strata of age, adjusting for sex. Conclusions Our data suggest that longer ART exposure was associated with increased risk of dyslipidemia, hypertension, and osteopenia/osteoporosis, hence the presence of multimorbidity, possibly due to the exposition to more toxic antiretrovirals. We observed different comorbidities, according to ART exposure and age

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

ObjectivesThe development of novel antiviral agents active against Hepatitis Delta Virus (HDV) might change the natural history of chronic infection, reducing the risk for end-stage liver disease. People living with HIV (PWH) are at risk for bloodborne pathogens infection, but limited data on epidemiology of HDV infection is available in this setting. The aim of this study was to investigate HDV prevalence and attitude toward HDV testing and treatment in infectious diseases centers.MethodsA cross sectional survey was performed among centers participating in the CISAI (Coordinamento Italiano per lo Studio dell’Allergia in Infezione da HIV) Group. The survey addressed anti-HDV prevalence and HDV-RNA detectability rates in PWH as well as perceived obstacles to treatment.ResultsOverall, responses from ten sites were collected. Among participating centers, 316 PWH with HBV chronic infection are currently followed. Of them, 15.2% had positive anti-HDV antibodies, while 13.9% were not tested yet. Overall, 17% of anti-HDV positive PWH tested at least once for HDV-RNA had active HDV infection, and 71% of them had advanced liver disease. Most infectious diseases centers intend to treat locally HDV infection with upcoming anti-HDV drugs, but some concerns exist regarding treatment schedule.DiscussionHDV testing needs to be implemented in PWH. At present, few patients followed in the CISAI centers seem to be candidate to receive new direct active anti-HDV agents, but repeated HDV-RNA measures could change this proportion